UB Paderborn / Katalog / Suche / in CDI

Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues

Scientific reports, 2021-02, Vol.11 (1), p.4530-4530, Article 4530

2021

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis

Supportive care in cancer, 2020-04, Vol.28 (4), p.1755-1764

2020

Link zum Volltext

Verfügbarkeit prüfen

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Cell reports. Medicine, 2023-12, Vol.4 (12), p.101332-101332, Article 101332

2023

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Einstein (São Paulo, Brazil), 2019-03, Vol.17 (2), p.eGS4414

2019

Link zum Volltext

Verfügbarkeit prüfen

Hypotensive Activity of Terpenes Found in Essential Oils

Zeitschrift für Naturforschung C. A journal of biosciences, 2010-10, Vol.65 (9), p.562-566

2010

Link zum Volltext

Verfügbarkeit prüfen

Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study

São Paulo medical journal, 2019-11, Vol.137 (6), p.505-511

2019

Link zum Volltext

Verfügbarkeit prüfen

Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis

Future Oncology, 2016-12, Vol.12 (23), p.2755-2764

2016

Link zum Volltext

Verfügbarkeit prüfen

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Drugs in context, 2018-11, Vol.7, p.212555-212555

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

ESMO open, 2017, Vol.2 (3), p.e000200, Article e000200

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges

Clinical Medicine Insights: Urology, 2018-01, Vol.11, p.117956111876575

2018

Link zum Volltext

Verfügbarkeit prüfen

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Einstein (São Paulo, Brazil), 2017-07, Vol.15 (3), p.349-354

2017

Link zum Volltext

Verfügbarkeit prüfen

Lag3: From Bench to Bedside

Cancer Immunotherapies, 2022, Vol.183, p.185-199

2022

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of placebo for the treatment of cancer-related fatigue: A systematic review and meta-analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23157-e23157

2019

Link zum Volltext

Verfügbarkeit prüfen

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3105-3105

2023

Link zum Volltext

Verfügbarkeit prüfen

Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e14532-e14532

2023

Link zum Volltext

Verfügbarkeit prüfen

Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.6615-6615

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3857: Characterization of immune cell biomarkers in undifferentiated pleomorphic sarcoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3857-3857

2020

Link zum Volltext

Verfügbarkeit prüfen

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S245

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S247-S248

2016

Link zum Volltext

Verfügbarkeit prüfen

PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S171-S172

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S246

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis: Track: Immunotherapy

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S247-S248

2016

Link zum Volltext

Verfügbarkeit prüfen

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S245-S245

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues

The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Hypotensive Activity of Terpenes Found in Essential Oils

Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study

Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets

Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

Lag3: From Bench to Bedside

The efficacy of placebo for the treatment of cancer-related fatigue: A systematic review and meta-analysis

RAF-inhibitor rechallenge therapy in BRAF aberrated pan-cancers: RE-RAFFLE study

Predictors of survival outcomes in patients (pts) with advanced solid tumors treated with cellular therapies in early clinical trials

Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer

Abstract 3857: Characterization of immune cell biomarkers in undifferentiated pleomorphic sarcoma

Abstract CT204: High cytotoxic T-cell or polymorphonuclear cell infiltrates in the tumor microenvironment correlate with responses to BL8040 plus pembrolizumab combination therapy in metastatic pancreatic tumors: Scientific correlates of a phase II clinical trial

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER

P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis

PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis

P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil

P2.47 (also presented as PD1.02): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis: Track: Immunotherapy

P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER: Track: Immunotherapy

Suchergebnisse filtern